Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNLX NASDAQ:SLDB NASDAQ:TERN NASDAQ:TRML On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNLXGenelux$3.42-1.7%$3.36$1.95▼$5.89$129.17M-0.33175,548 shs43,750 shsSLDBSolid Biosciences$5.50-1.1%$5.90$2.41▼$8.65$429.06M2.541.84 million shs759,902 shsTERNTerns Pharmaceuticals$7.17+1.5%$5.85$1.87▼$11.40$625.87M-0.041.16 million shs413,579 shsTRMLTourmaline Bio$27.22+8.4%$20.55$11.56▼$29.79$698.51M2.04281,387 shs309,828 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNLXGenelux+5.14%-1.42%-1.42%+35.94%+46.84%SLDBSolid Biosciences-3.30%-1.07%-17.01%+22.47%-34.59%TERNTerns Pharmaceuticals-5.11%-0.14%+16.12%+90.81%-3.68%TRMLTourmaline Bio-0.04%+8.99%+11.95%+30.25%+53.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNLXGenelux$3.42-1.7%$3.36$1.95▼$5.89$129.17M-0.33175,548 shs43,750 shsSLDBSolid Biosciences$5.50-1.1%$5.90$2.41▼$8.65$429.06M2.541.84 million shs759,902 shsTERNTerns Pharmaceuticals$7.17+1.5%$5.85$1.87▼$11.40$625.87M-0.041.16 million shs413,579 shsTRMLTourmaline Bio$27.22+8.4%$20.55$11.56▼$29.79$698.51M2.04281,387 shs309,828 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNLXGenelux+5.14%-1.42%-1.42%+35.94%+46.84%SLDBSolid Biosciences-3.30%-1.07%-17.01%+22.47%-34.59%TERNTerns Pharmaceuticals-5.11%-0.14%+16.12%+90.81%-3.68%TRMLTourmaline Bio-0.04%+8.99%+11.95%+30.25%+53.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNLXGenelux 3.00Buy$20.33494.54% UpsideSLDBSolid Biosciences 3.09Buy$15.00172.88% UpsideTERNTerns Pharmaceuticals 2.60Moderate Buy$15.61117.86% UpsideTRMLTourmaline Bio 3.00Buy$50.1484.21% UpsideCurrent Analyst Ratings BreakdownLatest GNLX, SLDB, TERN, and TRML Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025TERNTerns PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$7.448/14/2025SLDBSolid BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.008/14/2025SLDBSolid BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$15.00 ➝ $13.008/14/2025TRMLTourmaline BioChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.008/14/2025TRMLTourmaline BioGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$55.008/13/2025SLDBSolid BiosciencesWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$17.00 ➝ $14.007/23/2025GNLXGeneluxHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/21/2025SLDBSolid BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$16.006/26/2025SLDBSolid BiosciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$14.006/26/2025SLDBSolid BiosciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$14.006/17/2025SLDBSolid BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.00(Data available from 9/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNLXGenelux$10K12,917.34N/AN/A$0.76 per share4.50SLDBSolid Biosciences$8.09M52.91N/AN/A$3.43 per share1.60TERNTerns PharmaceuticalsN/AN/AN/AN/A$4.07 per shareN/ATRMLTourmaline BioN/AN/AN/AN/A$11.71 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNLXGenelux-$29.87M-$0.86N/AN/AN/AN/A-107.47%-83.14%11/13/2025 (Estimated)SLDBSolid Biosciences-$124.70M-$2.80N/AN/AN/AN/A-69.70%-56.74%11/5/2025 (Estimated)TERNTerns Pharmaceuticals-$88.85M-$1.04N/AN/AN/AN/A-27.35%-26.18%11/11/2025 (Estimated)TRMLTourmaline Bio-$73.21M-$3.43N/AN/AN/AN/A-30.50%-29.63%11/6/2025 (Estimated)Latest GNLX, SLDB, TERN, and TRML EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025TRMLTourmaline Bio-$0.94-$0.90+$0.04-$0.90N/AN/A8/12/2025Q2 2025SLDBSolid Biosciences-$0.51-$0.42+$0.09-$0.42N/AN/A8/7/2025Q2 2025GNLXGenelux-$0.22-$0.20+$0.02-$0.20N/AN/A8/5/2025Q2 2025TERNTerns Pharmaceuticals-$0.28-$0.26+$0.02-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGNLXGeneluxN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/AN/ATRMLTourmaline BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNLXGeneluxN/A4.184.18SLDBSolid BiosciencesN/A9.349.34TERNTerns PharmaceuticalsN/A24.7024.70TRMLTourmaline BioN/A24.6824.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNLXGenelux37.33%SLDBSolid Biosciences81.46%TERNTerns Pharmaceuticals98.26%TRMLTourmaline Bio91.89%Insider OwnershipCompanyInsider OwnershipGNLXGenelux8.80%SLDBSolid Biosciences1.90%TERNTerns Pharmaceuticals1.50%TRMLTourmaline Bio13.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNLXGenelux1037.77 million34.45 millionNot OptionableSLDBSolid Biosciences10077.87 million76.39 millionOptionableTERNTerns Pharmaceuticals4087.51 million86.20 millionNot OptionableTRMLTourmaline Bio4425.69 million22.35 millionOptionableGNLX, SLDB, TERN, and TRML HeadlinesRecent News About These CompaniesJump Financial LLC Makes New Investment in Tourmaline Bio, Inc. $TRMLSeptember 4 at 3:56 AM | marketbeat.comNuveen LLC Invests $1.18 Million in Tourmaline Bio, Inc. $TRMLSeptember 3 at 3:38 AM | marketbeat.comTourmaline Bio, Inc. $TRML is QVT Financial LP's 7th Largest PositionSeptember 2 at 9:40 AM | marketbeat.comVanguard Group Inc. Buys 84,685 Shares of Tourmaline Bio, Inc. $TRMLSeptember 1, 2025 | marketbeat.comTourmaline Bio highlights positive phase 2 pacibekitug dataSeptember 1, 2025 | msn.comTourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology CongressAugust 31, 2025 | globenewswire.comTourmaline Bio, Inc. $TRML Shares Bought by Velan Capital Investment Management LPAugust 31, 2025 | marketbeat.comEntryPoint Capital LLC Invests $380,000 in Tourmaline Bio, Inc. $TRMLAugust 23, 2025 | marketbeat.comAnalysts Set Expectations for Tourmaline Bio FY2025 EarningsAugust 19, 2025 | marketbeat.comTourmaline Bio Q3 EPS Forecast Raised by Leerink PartnrsAugust 19, 2025 | marketbeat.comLifesci Capital Expects Higher Earnings for Tourmaline BioAugust 19, 2025 | marketbeat.comWhat is Wedbush's Forecast for Tourmaline Bio Q3 Earnings?August 19, 2025 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Issues Quarterly Earnings Results, Beats Expectations By $0.04 EPSAugust 17, 2025 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Receives "Buy" Rating from Chardan CapitalAugust 16, 2025 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Receives Buy Rating from GuggenheimAugust 16, 2025 | marketbeat.comWall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's What You Should KnowAugust 15, 2025 | zacks.comTourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Recommendation of "Buy" by BrokeragesAugust 14, 2025 | marketbeat.comTourmaline Bio Reports Positive Trial Results and Strong Cash PositionAugust 13, 2025 | tipranks.comTourmaline Bio, Inc.: Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business HighlightsAugust 13, 2025 | finanznachrichten.deTourmaline Bio reports Q2 EPS (90c), consensus (93c)August 13, 2025 | msn.comTourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business HighlightsAugust 13, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesHow Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go?By Jordan Chussler | August 14, 2025Tesla Is Balanced on a Knife Edge: Time to Tread CarefullyBy Sam Quirke | August 8, 2025Amazon’s Chart Just Flashed a Pennant Pattern—Here’s What to DoBy Sam Quirke | August 27, 2025Chevron Stock Outlook: Dividend Growth Meets InflationBy Chris Markoch | August 28, 2025How a Superstore Strategy Fueled MINISO’s 20% Stock SurgeBy Jeffrey Neal Johnson | August 26, 2025GNLX, SLDB, TERN, and TRML Company DescriptionsGenelux NASDAQ:GNLX$3.42 -0.06 (-1.72%) As of 02:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.Solid Biosciences NASDAQ:SLDB$5.50 -0.06 (-1.13%) As of 03:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.Terns Pharmaceuticals NASDAQ:TERN$7.16 +0.11 (+1.49%) As of 03:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.Tourmaline Bio NASDAQ:TRML$27.22 +2.12 (+8.45%) As of 02:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Microsoft’s AI Push Beyond OpenAI Could Drive Next Breakout Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
